Entry and Fusion Inhibitors
Last Updated: May 22, 2018; Last Reviewed: May 22, 2018
Maraviroc (MVC, Selzentry)
|Maraviroc (MVC, Selzentry)
For additional information see Drugs@FDA: http://www.accessdata.fda.gov/scripts/cder/daf/
|Tablets: 25 mg, 75 mg, 150 mg, and 300 mg
Oral Solution: 20 mg/mL
||Selected Adverse Events
|Neonate and Infant Dose:
- Not approved for use in neonates or infants
- Approved for use in treatment-experienced children aged ≥2 years and weighing ≥10 kg
Recommended Maraviroc Dose for Treatment-Experienced Children Aged ≥2 Years and Weighing ≥10 kg: Tablets or Oral Solution
Recommended Adult Maraviroc Dose: Tablets
- Nausea, vomiting
- Abdominal pain, diarrhea
- Upper respiratory tract infections
- Hepatotoxicity (which may be preceded by severe rash and/or other signs of systemic allergic reaction)
- Postural hypotension (generally seen in patients with severe renal insufficiency)
- Maraviroc is recommended for patients with only CCR5-tropic HIV-1. Conduct testing with HIV tropism assay (see Drug-Resistance Testing in the Adult and Adolescent Guidelines) before using maraviroc to exclude the presence of CXCR4-tropic or mixed/dual-tropic HIV. Do not use maraviroc if CXCR4-tropic or mixed/dual-tropic HIV is present.
- Maraviroc can be given without regard to food.
- Instruct patients on how to recognize symptoms of allergic reactions or hepatitis.
- Use caution when administering maraviroc to patients with underlying cardiac disease.
Maraviroc Dosing in Patients with Hepatic Impairment:
- Cytochrome P450 3A4 (CYP3A4) substrate
Maraviroc Dosing in Adolescents and Adults with Renal Impairment:
- Use caution when administering maraviroc to patients with hepatic impairment; maraviroc concentrations may be increased.
- Refer to the manufacturer’s prescribing information.
- Data are insufficient to make dosing recommendations for use of maraviroc in children concomitantly receiving noninteracting medications and weighing <30 kg or in all children concomitantly receiving potent CYP3A inducers without a potent CYP3A inhibitor.